2007 - Review: Evidence for the effectiveness of anticoagulation therapy or prophylaxis for VTE in cancer is limited

Wells, Philip S.
May 2008
ACP Journal Club;5/20/2008, Vol. 148 Issue 3, p6
Academic Journal
Case Study
The article presents information on a case study that was conducted to analyze whether anticoagulants are effective for preventing and treating venous thromboembolism (VTE) in patients with cancer. Randomized controlled trials evaluated low-molecular-weight heparin (LMWH), unfractionated heparin, or an oral vitamin K antagonist (VKA) in adults with cancer.


Related Articles

  • Pharmacological Strategies for Inhibition of Thrombin Activity. Alban, S. // Current Pharmaceutical Design;Apr2008, Vol. 14 Issue 12, p1152 

    For decades, the options for therapeutic anticoagulation were limited to unfractionated heparin (UFH) and vitamin K antagonists (VKA), and their well-known limitations had to be accepted. With the introduction of the various LMWHs, the short-term anticoagulation could be much improved. The...

  • Pharmacology and Clinical Potential of Direct Thrombin Inhibitors. Linkins, Lori-Ann; Weitz, Jeffrey I. // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 30, p3877 

    Direct thrombin inhibitors represent a new class of anticoagulants that bind directly to thrombin and block the enzyme's interactions with its substrates. These agents have been developed, at least in part, to overcome the limitations of heparin and vitamin K antagonists. This paper (a) reviews...

  • Direct Thrombin Inhibitors for the Prevention of Venous Thromboembolism after Major Orthopaedic Surgery. Agnelli, Giancarlo; Sonaglia, Francesco; Becattini, Cecilia // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 30, p3885 

    Unfractionated heparin, low-molecular-weight heparins and vitamin K antagonists are established antithrombotic agents, but all have a number of limitations. Unfractionated heparin requires parenteral administration, has a short half-life and variable dose-response relationship. Low molecular...

  • Heterogeneity of Synthetic Factor Xa Inhibitors. Gerotziafas, G. T.; Samama, M. M. // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 30, p3855 

    Heparins and vitamin K antagonists are the landmarks of antithrombotic treatment. Both of them were discovered by serendipity; they are multi-targeted drugs and share several limitations. New molecules have been designed in order to be both more selective concerning their biological target and...

  • Editorial [Hot Topic: Novel Factor Xa-and Thrombin-Inhibitors (Executive Editor: Giuseppe G. Nenci)]. Nenci, Giuseppe G. // Current Pharmaceutical Design;Nov2005, Vol. 11 Issue 30, p3853 

    Focuses on the role of vitamin K and heparin in the field of anticoagulation. Citations of the aspects which limit their efficacy and practicality of use; Preparation of low-molecular weight fractions of standard heparin; Reason on why vitamin K antagonists are often subtracted from patients...

  • Managing Bleeding Complications in Patients Treated with the Old and the New Anticoagulants. Romualdi, Erica; Rancan, Elena; Siragusa, Sergio; Ageno, Walter // Current Pharmaceutical Design;10/21/2010, Vol. 16 Issue 31, p3478 

    No abstract available.

  • New Anticoagulants: Focus on Venous Thromboembolism. G�mez-Outes, Antonio; Lecumberri, Ram�n; Pozo, Carmen; Rocha, Eduardo // Current Vascular Pharmacology;Jul2009, Vol. 7 Issue 3, p309 

    Anticoagulation is recommended for prophylaxis and treatment of venous thromboembolism (VTE) (deep vein thrombosis and pulmonary embolism) and/or arterial thromboembolism. The therapeutic arsenal of anticoagulants available to clinicians is mainly composed by unfractionated heparin (UFH),...

  • Secondary Prophylaxis with Warfarin for Venous Thromboembolism. Büller, Harry R.; Prins, Martin H. // New England Journal of Medicine;8/14/2003, Vol. 349 Issue 7, p702 

    Editorial. Offers an editorial on the two phases in the treatment of patients with symptomatic venous thromboembolism. Therapy that consists of either subcutanous low-molecular-weight heparin or intravenous unfractionated heparin; Phase involving oral vitamin K antagonists such as warfarin;...

  • LMWH + vit K antagonist the better option for VTE.  // PharmacoEconomics & Outcomes News;7/30/2005, Issue 483, p5 

    Provides information on research regarding the anticoagulation cost of low molecular weight heparin (LMWH) plus a vitamin K antagonist (VKA). Hospitalisation costs of LMWH plus VKA in patients admitted with venous thromboembolism; Comparison of the mean coagulation costs in patients with deep...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics